ReviewCurrent opinion in investigational drugs (London, England : 2000)2008
Signaling cascades as drug targets in model and pathogenic fungi.
Review in Current opinion in investigational drugs (London, England : 2000), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Molecular Strategies and Regulatory Networks in the Early Infection Stages of Plant Pathogenic Fusarium Species.The plant pathology journal · 2026Review
- Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi.Frontiers in cellular and infection microbiology · 2023Article
- In Vitro Interaction of Geldanamycin with Triazoles and Echinocandins Against Common and Emerging Candida Species.Mycopathologia · 2019Article
- Functional Characterization of Target of Rapamycin Signaling inFrontiers in microbiology · 2019Article
- Virulence Factors as Targets for Anticryptococcal Therapy.Journal of fungi (Basel, Switzerland) · 2016Review
- The Mechanistic Targets of Antifungal Agents: An Overview.Mini reviews in medicinal chemistry · 2016Review
- Advances against aspergillosis: biology, host response, diagnosis and treatment.Mycopathologia · 2014Article
- Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options.The Lancet. Infectious diseases · 2014Review
- Calcineurin as a Multifunctional Regulator: Unraveling Novel Functions in Fungal Stress Responses, Hyphal Growth, Drug Resistance, and Pathogenesis.Fungal biology reviews · 2014Article
- pH signaling in human fungal pathogens: a new target for antifungal strategies.Eukaryotic cell · 2014Review
- Regulation of cation balance in Saccharomyces cerevisiae.Genetics · 2013Review
- Novel Regulatory Mechanisms of Pathogenicity and Virulence to Combat MDR in Candida albicans.International journal of microbiology · 2013Review
- Role of Ess1 in growth, morphogenetic switching, and RNA polymerase II transcription in Candida albicans.PloS one · 2013Article
- Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor.Eukaryotic cell · 2012Article
- Sensing of mammalian IL-17A regulates fungal adaptation and virulence.Nature communications · 2012Article
- Article
- Acidic calcium stores of Saccharomyces cerevisiae.Cell calcium · 2011Review
- Conservation, duplication, and loss of the Tor signaling pathway in the fungal kingdom.BMC genomics · 2010Article
- The protein kinase Tor1 regulates adhesin gene expression in Candida albicans.PLoS pathogens · 2009Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Microbes evolved to produce natural products that inhibit growth of competing soil microorganisms. In many cases these compounds act on fungi, which are eukaryotes with conserved gene sequences closely related to metazoans, including humans. The calcineurin inhibitors cyclosporin A and FK-506, the Tor inhibitor rapamycin, and the Hsp90 inhibitor geldanamycin, all act via targets conserved from yeast to humans. This allows the use of genetically tractable fungi as models to elucidate how these drugs and their targets function in yeast and human cells. These inhibitors also enable studies aimed at harnessing their intrinsic antimicrobial activities to develop novel antifungal therapies. Extensive studies have revealed a globally conserved role for the Tor protein in regulating growth and proliferation in response to nutrients, and targeting its essential functions results in robust antifungal action. Similarly, a conserved and essential role for calcineurin in fungal virulence has been established and could be targeted by inhibitors for therapeutic uses in a variety of clinical settings. Finally, the discovery that inhibitors of calcineurin or Hsp90 result in dramatic synergism with either azoles or glucan synthase inhibitors (candins) provides another therapeutic vantage point. Taken together, these fungal targets and their inhibitors provide a robust platform from which to develop novel antimicrobial therapies.
Indexed as
Identifiers
18666033PMC2715221W38488696What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.